Nonalcoholic fatty liver disease
Compared with a normal liver (left), a fatty liver (right) appears enlarged and discolored. Tissue samples reveal fat deposits in nonalcoholic fatty liver disease, while inflammation and advanced scarring (cirrhosis) are visible in nonalcoholic steatohepatitis.
Nonalcoholic fatty liver disease (NAFLD) is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. As the name implies, the main characteristic of NAFLD is too much fat stored in liver cells.
NAFLD is increasingly common around the world, especially in Western nations. In the United States, it is the most common form of chronic liver disease, affecting about one-quarter of the population.
Some individuals with NAFLD can develop nonalcoholic steatohepatitis (NASH), an aggressive form of fatty liver disease, which is marked by liver inflammation and may progress to advanced scarring (cirrhosis) and liver failure. This damage is similar to the damage caused by heavy alcohol use.
Products & Services
The liver is your largest internal organ. About the size of a football, it's located mainly in the upper right portion of your abdomen — beneath the diaphragm and above your stomach. A small portion extends into the upper left quadrant.
NAFLD usually causes no signs and symptoms. When it does, they may include:
- Pain or discomfort in the upper right abdomen
Possible signs and symptoms of NASH and advanced scarring (cirrhosis) include:
- Abdominal swelling (ascites)
- Enlarged blood vessels just beneath the skin's surface
- Enlarged spleen
- Red palms
- Yellowing of the skin and eyes (jaundice)
When to see a doctor
Make an appointment with your doctor if you have persistent signs and symptoms that cause you concern.
Get the latest health information from Mayo Clinic delivered to your inbox.
Subscribe for free and receive your in-depth guide to
digestive health, plus the latest on health innovations and news. You can unsubscribe at any
ErrorEmail field is required
ErrorInclude a valid email address
To provide you with the most relevant and helpful information, and understand which
information is beneficial, we may combine your email and website usage information with
other information we have about you. If you are a Mayo Clinic patient, this could
include protected health information. If we combine this information with your protected
health information, we will treat all of that information as protected health
information and will only use or disclose that information as set forth in our notice of
privacy practices. You may opt-out of email communications at any time by clicking on
the unsubscribe link in the e-mail.
Thank you for subscribing
Your in-depth digestive health guide will be in your inbox shortly. You will also receive
emails from Mayo Clinic on the latest health news, research, and care.
If you don’t receive our email within 5 minutes, check your SPAM folder, then contact us
Sorry something went wrong with your subscription
Please, try again in a couple of minutes
Experts don't know exactly why some people accumulate fat in the liver while others do not. Similarly, there is limited understanding of why some fatty livers develop inflammation that progresses to cirrhosis.
NAFLD and NASH are both linked to the following:
- Overweight or obesity
- Insulin resistance, in which your cells don't take up sugar in response to the hormone insulin
- High blood sugar (hyperglycemia), indicating prediabetes or type 2 diabetes
- High levels of fats, particularly triglycerides, in the blood
These combined health problems appear to promote the deposit of fat in the liver. For some people, this excess fat acts as a toxin to liver cells, causing liver inflammation and NASH, which may lead to a buildup of scar tissue in the liver.
A wide range of diseases and conditions can increase your risk of NAFLD, including:
- High cholesterol
- High levels of triglycerides in the blood
- Metabolic syndrome
- Obesity, particularly when fat is concentrated in the abdomen
- Polycystic ovary syndrome
- Sleep apnea
- Type 2 diabetes
- Underactive thyroid (hypothyroidism)
- Underactive pituitary gland (hypopituitarism)
NASH is more likely in these groups:
- Older people
- People with diabetes
- People with body fat concentrated in the abdomen
It is difficult to distinguish NAFLD from NASH without further testing.
Normal liver vs. liver cirrhosis
A typical liver (left) shows no signs of scarring. In cirrhosis (right), scar tissue replaces typical liver tissue.
Esophageal varices are enlarged veins in the esophagus. They're often due to obstructed blood flow through the portal vein, which carries blood from the intestine, pancreas and spleen to the liver.
Liver cancer begins in the cells of the liver. The most common form of liver cancer begins in cells called hepatocytes and is called hepatocellular carcinoma.
The main complication of NAFLD and NASH is cirrhosis, which is late-stage scarring in the liver. Cirrhosis occurs in response to liver injury, such as the inflammation in NASH. As the liver tries to halt inflammation, it produces areas of scarring (fibrosis). With continued inflammation, fibrosis spreads to take up more and more liver tissue.
If the process isn't interrupted, cirrhosis can lead to:
- Fluid buildup in the abdomen (ascites)
- Swelling of veins in your esophagus (esophageal varices), which can rupture and bleed
- Confusion, drowsiness and slurred speech (hepatic encephalopathy)
- Liver cancer
- End-stage liver failure, which means the liver has stopped functioning
Between 5% and 12% of people with NASH will progress to cirrhosis.
To reduce your risk of NAFLD:
- Choose a healthy diet. Choose a healthy plant-based diet that's rich in fruits, vegetables, whole grains and healthy fats.
- Maintain a healthy weight. If you are overweight or obese, reduce the number of calories you eat each day and get more exercise. If you have a healthy weight, work to maintain it by choosing a healthy diet and exercising.
- Exercise. Exercise most days of the week. Get an OK from your doctor first if you haven't been exercising regularly.
Sept. 22, 2021